CD4+ T helper (Th) cells regulate multiple aspects of adaptive cell mediated immunity through the secretion of specific subsets of cytokines. While their activities are critical in responses to pathogenic organisms, CD4+ T cells can also mediate pathologies associated with various inflammatory processes. Specifically, Th2 cells are the key subset of cells that orchestrate the inflammation of asthma through the secretion of the effector cytokines IL-4, IL-5, and IL-13. IL-4 drives Th2 development in CD4+ T cells through the induction of a key transcription factor GATA3. Unlike the innate cytokines IL-12 and IFN-3, we have recently demonstrated that type I interferon (IFN-1/2) inhibits the development and phenotype stability of IL-4-driven Th2 cells. We further demonstrate that IFN-1 blocks this developmental pathway by repressing GATA3 expression. Based on our findings, we propose that IFN-1/2 could block cytokine secretion of asthmatic Th2 cells and reverse the pathogenic effects in vivo. We will address this hypothesis with the following aims:
Aim 1 : Characterize the phenotype and function of Th2 cells undergoing redirection with IFN-1/2.
Aim 2 : Determine the molecular mechanism by which IFN-1/2 blocks GATA3 expression.
Aim 3 : Determine the ability of IFN-1/2 to inhibit phenotype stability and cytokine secretion from Th2 cells isolated from asthmatic patients. The results from these studies will form the basis for new therapeutic approaches to treat asthma involving IFN-1/2.

Public Health Relevance

Asthma is a debilitating inflammatory disease of the lungs that affects millions of people worldwide. While various therapies are in place to provide temporary relief, and in some cases immediate life- saving intervention with inhalers, no treatment has been developed that blocks the chronic progression and maintenance of the disease. Asthma is an immune-mediated disorder caused by the inappropriate activation of CD4+ T cells to normally innocuous molecules in the environment. These activated T cells secrete soluble cytokines, such as interleukin-4, that activate a cascade of inflammatory processes in the lung. Thus, CD4+ T cells represent the primary target for reversing the pathogenesis of asthma. In our studies, we have found that a unique cytokine, type I interferon (IFN- a/b), potently blocks the development of these inflammatory T cells and inhibits their ability to secrete cytokines. Based on this observation, this proposal seeks to understand the mechanism by which IFN-a/b reverses these pathogenic T cells and will determine whether IFN-a/b can block cytokine secretion from these inflammatory T cells isolated from asthma sufferers. These studies will lay the groundwork for more effective and long-lasting treatment for allergy and asthma.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
3R01AI056222-09S1
Application #
8703230
Study Section
Hypersensitivity, Autoimmune, and Immune-mediated Diseases Study Section (HAI)
Program Officer
Davidson, Wendy F
Project Start
2003-07-01
Project End
2015-01-31
Budget Start
2013-08-25
Budget End
2014-01-31
Support Year
9
Fiscal Year
2013
Total Cost
$39,014
Indirect Cost
$13,436
Name
University of Texas Sw Medical Center Dallas
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Chowdhury, Fatema Z; Estrada, Leonardo D; Murray, Sean et al. (2014) Pharmacological inhibition of TPL2/MAP3K8 blocks human cytotoxic T lymphocyte effector functions. PLoS One 9:e92187
Huber, Jonathan P; Gonzales-van Horn, Sarah R; Roybal, Kole T et al. (2014) IFN-? suppresses GATA3 transcription from a distal exon and promotes H3K27 trimethylation of the CNS-1 enhancer in human Th2 cells. J Immunol 192:5687-94
Pyle, David M; Yang, Victoria S; Gruchalla, Rebecca S et al. (2013) IgE cross-linking critically impairs human monocyte function by blocking phagocytosis. J Allergy Clin Immunol 131:491-500.e1-5
Chowdhury, Fatema Z; Farrar, J David (2013) STAT2: A shape-shifting anti-viral super STAT. JAKSTAT 2:e23633
Chowdhury, Fatema Z; Ramos, Hilario J; Davis, Laurie S et al. (2011) IL-12 selectively programs effector pathways that are stably expressed in human CD8+ effector memory T cells in vivo. Blood 118:3890-900
Huber, Jonathan P; Ramos, Hilario J; Gill, Michelle A et al. (2010) Cutting edge: Type I IFN reverses human Th2 commitment and stability by suppressing GATA3. J Immunol 185:813-7
Ramos, Hilario J; Davis, Ann M; Cole, Alexander G et al. (2009) Reciprocal responsiveness to interleukin-12 and interferon-alpha specifies human CD8+ effector versus central memory T-cell fates. Blood 113:5516-25
Davis, Ann M; Hagan, Kristan A; Matthews, Loderick A et al. (2008) Blockade of virus infection by human CD4+ T cells via a cytokine relay network. J Immunol 180:6923-32
Davis, Ann M; Ramos, Hilario J; Davis, Laurie S et al. (2008) Cutting edge: a T-bet-independent role for IFN-alpha/beta in regulating IL-2 secretion in human CD4+ central memory T cells. J Immunol 181:8204-8
Ramos, Hilario J; Davis, Ann M; George, Thaddeus C et al. (2007) IFN-alpha is not sufficient to drive Th1 development due to lack of stable T-bet expression. J Immunol 179:3792-803

Showing the most recent 10 out of 11 publications